Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  venetoclax
Find trials that include:  Any drugs shown
Results 1-10 of 10 for your search:
Start Over
A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GO27878, NCI-2016-00590, NCT02055820
Venetoclax in Combination with Obinutuzumab and Ibrutinib in Treating Patients with Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU-14266, NCI-2015-00252, ML29533, NCT02427451
A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 60 and over
Trial IDs: GH29914, NCI-2016-00260, 2015-003386-28, NCT02670044
Venetoclax in Treating Patients with Relapsed or Refractory Waldenstrom Macroglobulinemia
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 15-491, NCI-2016-00699, NCT02677324
Venetoclax and Ibrutinib in Treating Patients with Chronic or Small Lymphocytic Leukemia
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2015-0860, NCI-2016-00797, NCT02756897
A Study of Venetoclax (GDC-0199, ABT-199) in Combination With Bendamustine And MabThera/Rituxan in Participants With Chronic Lymphocytic Leukemia
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GO28440, NCI-2013-01974, 2012-002351-42, NCT01671904
Study Evaluating ABT-199 in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: M13-367, NCI-2012-03142, 2012-000589-38, NCT01794520
Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo)
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 65 and over
Trial IDs: M14-358, NCI-2014-01763, 2014-000687-18, NCT02203773
A Study of Obinutuzumab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GO29833, NCI-2015-02093, 2015-001998-40, NCT02611323
Start Over